AU2002362383B2 - Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies - Google Patents

Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies Download PDF

Info

Publication number
AU2002362383B2
AU2002362383B2 AU2002362383A AU2002362383A AU2002362383B2 AU 2002362383 B2 AU2002362383 B2 AU 2002362383B2 AU 2002362383 A AU2002362383 A AU 2002362383A AU 2002362383 A AU2002362383 A AU 2002362383A AU 2002362383 B2 AU2002362383 B2 AU 2002362383B2
Authority
AU
Australia
Prior art keywords
lysine
sequence seq
serine
acetylated
phosphorylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002362383A
Other languages
English (en)
Other versions
AU2002362383A1 (en
Inventor
Jean-Paul Briand
Gilles Guichard
Jean-Gerard Guillet
Fanny Sylvie Michele Monneaux
Sylviane Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Centre National de la Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique filed Critical Centre National de la Recherche Scientifique
Publication of AU2002362383A1 publication Critical patent/AU2002362383A1/en
Application granted granted Critical
Publication of AU2002362383B2 publication Critical patent/AU2002362383B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2002362383A 2001-09-18 2002-09-18 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies Expired AU2002362383B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/12041 2001-09-18
FR0112041A FR2829768B1 (fr) 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
PCT/FR2002/003186 WO2003025014A2 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Publications (2)

Publication Number Publication Date
AU2002362383A1 AU2002362383A1 (en) 2003-06-05
AU2002362383B2 true AU2002362383B2 (en) 2008-10-09

Family

ID=8867384

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002362383A Expired AU2002362383B2 (en) 2001-09-18 2002-09-18 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies

Country Status (7)

Country Link
US (3) US7872098B1 (cg-RX-API-DMAC10.html)
EP (2) EP2338908A1 (cg-RX-API-DMAC10.html)
JP (1) JP4160505B2 (cg-RX-API-DMAC10.html)
AU (1) AU2002362383B2 (cg-RX-API-DMAC10.html)
CA (1) CA2460704A1 (cg-RX-API-DMAC10.html)
FR (1) FR2829768B1 (cg-RX-API-DMAC10.html)
WO (1) WO2003025014A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459811C (en) * 2001-09-06 2012-03-13 Cnrs-Centre National De La Recherche Scientifique Modified peptides and their use for the treatment of autoimmune diseases
FR2931360B1 (fr) * 2008-05-20 2012-05-18 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
ES2618402T3 (es) * 2011-12-13 2017-06-21 Centre National De La Recherche Scientifique Péptidos modificados y su uso para tratar enfermedades autoinmunitarias
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
WO2021198135A1 (en) * 2020-03-29 2021-10-07 Immupharma France Sa Method of treating viral infections
CN119241701B (zh) * 2024-09-27 2026-04-28 珠海丽禾医疗诊断产品有限公司 U1-70k结合蛋白、制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459811C (en) * 2001-09-06 2012-03-13 Cnrs-Centre National De La Recherche Scientifique Modified peptides and their use for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
WO2003025014A3 (fr) 2004-02-19
JP2005510469A (ja) 2005-04-21
EP2338908A1 (fr) 2011-06-29
US20140004136A1 (en) 2014-01-02
FR2829768B1 (fr) 2003-12-12
US7872098B1 (en) 2011-01-18
EP1427755A2 (fr) 2004-06-16
WO2003025014A2 (fr) 2003-03-27
CA2460704A1 (fr) 2003-03-27
JP4160505B2 (ja) 2008-10-01
US8475800B2 (en) 2013-07-02
FR2829768A1 (fr) 2003-03-21
US20120149652A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
Mouthon et al. Mechanisms of action of intravenous immune globulin in immune‐mediated diseases
US6210669B1 (en) Methods and compositions for immunomodulation
US20080267965A1 (en) Use of Bcma as an Immunoregulatory Agent
US20140004136A1 (en) Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies
EP1004312A1 (en) Method for treating multiple sclerosis
AU721898B2 (en) Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein
JP2018508522A (ja) 抗炎症性ポリペプチド
EP0922057A1 (en) Myelin oligodendrocyte glycoprotein peptides and uses thereof
US5753625A (en) Treatment for inhibiting the progression of autoimmune disease
WO2016145086A1 (en) Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
JP4108601B2 (ja) 修飾ペプチドおよび自己免疫疾患を治療するためのその使用
Briand et al. Emerging peptide therapeutics for inflammatory autoimmune diseases
NZ336745A (en) A method of treating an animal with an autoimmune condition such as rheumatoid arthritis and relapsing polychrondritis
EP1082967B1 (en) Prevention and treatment of autoimmune demyelinating diseases by Fas-antagonists
JP2002521387A (ja) 共重合体１および関連する共重合体ならびにペプチドによる自己免疫疾患の治療
CN107106672B (zh) 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体
US9758557B2 (en) C1q peptides and uses thereof
EA019358B1 (ru) Аллель- и изотип-специфическая интервенция в ассоциированные с аутоиммунными заболеваниями молекулы класса ii мнс при помощи пептидов
Sitaraman Myasthenia gravis: Role of cytokines in disease and design of therapy
JPWO1999062554A1 (ja) 自己免疫性脱髄性疾患予防・治療剤
HK1028554A (en) Method for treating multiple sclerosis
AU3685899A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO2006052654A2 (en) Compositions and methods for the treatment of immune mediated diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired